Aiforia Technologies has appointed Swedbank AB (publ) as their lead financial advisor to explore different financing options, including possibilities for an Initial Public Offering (IPO) by listing the Company’s shares on Nasdaq Helsinki First North.
“Aiforia has reached significant milestones in its technology and work in scientific research and drug development since launching its artificial intelligence (AI) software for medical image analysis in 2018,” the company said in a statement.
The statement added, “The number of Aiforia users increased by 87% in 2020, to a total of over 3,000 in 50 countries. Notable customers include medical professionals from some of the world’s biggest pharmaceutical and biotechnology companies like Boehringer Ingelheim, Sanofi and Charles River Laboratories, as well as institutions such as MIT and the University of Sydney.”
“Exploring further financing options will help us strengthen our offering for clinical labs and pathologists. Our mission is to become a global leader in AI-powered diagnostics and to therefore alleviate the burden experienced by healthcare systems and patients around the world,” said Jukka Tapaninen, CEO of Aiforia Technologies.
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.